University at Buffalo

UB spinoff Cytocybernetics receives funding to accelerate COVID-19 drug screening

28-Oct-2020 11:35 AM EDT, by University at Buffalo

Newswise — BUFFALO, N.Y. — As COVID-19 infection rates and death tolls continue to rise, researchers and scientists around the world are racing to clear candidate drug therapies for COVID-19.

University at Buffalo spinoff Cytocybernetics is aiding in this effort by developing a high-tech tool called CyberQ to rapidly assess whether or not investigational COVID-19 drugs have arrhythmogenic properties that can result in sudden cardiac death — a critical step in the U.S. Food and Drug Administration’s drug approval process.

For this work, the company has been awarded $44,990 in supplemental COVID-19 funds through the National Science Foundation’s Small Business Technology Transfer (STTR) program. The funds are an amendment to an initial Phase I STTR award received by the company in June 2019, bringing Cytocybernetics’ total award sum for the project to $269,990.

“Since the late 1990s, all new drugs must demonstrate that they are safe and do not unreasonably increase the risk of sudden cardiac death. The FDA mandates cardiac risk information from all drug candidates, and most companies use a slow, laborious approach that was developed over 20 years ago,” says Glenna Bett, PhD, Cytocybernetics CEO and vice chair for research in the Department of Obstetrics and Gynecology in the Jacobs School of Medicine and Biomedical Sciences at UB.

To replace this outdated process, CyberQ utilizes advanced computer models and machine learning to quickly analyze electrophysiological data from a variety of in-vitro assays and accurately determine if new drugs may produce cardiac arrhythmias that could lead to patient death.

“The COVID situation requires quick answers to drug risk, but skipping or paying inadequate attention to this safety test can lead to serious problems, which may only become apparent when the drug is widely used. We are partnering with the FDA to produce a simple yet powerful analysis of drug data to determine the clinical risk of a drug candidate,” Bett explains. “This new process is designed to reduce the time to bring a drug to market, and to increase the clinical relevance of the preclinical drug safety testing, resulting in fewer post-market adverse events. Shortening the time and increasing the accuracy of this testing will bring down the cost of commercializing a candidate compound.”

Cytocybernetics senior software engineer Leigh Korbel, who graduated from UB with a master's in physics and advanced certification in computational science, is the lead investigator on the NSF-funded project.

According to Bett, the older FDA process for determining the cardiac safety of drug candidates often resulted in large errors in early stages of drug development, resulting in premature abandonment of promising drugs. Along with safety tests for new potential therapies, Cytocybernetics’ software uses artificial intelligence to reexamine old data to recognize such drugs.

"The net result is that drugs that were well along in development that have the potential to be part of the solution to COVID-19 can be ‘resurrected’ to fight the disease much more quickly than starting from scratch,” says Randall Rasmusson, PhD, co-founder of Cytocybernetics, and a professor of physiology and biophysics in Jacobs School of Medicine and Biomedical Sciences.

UB is dedicated to supporting startups founded on innovations from its faculty and students. In recent years, initiatives and programs led by the Office of Business and Entrepreneur Partnerships (BEP) have connected growing startups like Cytocybernetics with funding, space, facilities, expertise and business mentorship to help them reach key business milestones.

"We’re proud to see UB spinoff companies like Cytocybernetics making progress in developing technologies that solve an urgent market challenge and can impact millions of lives,” says Christina Orsi, UB associate vice president for economic development. “We’re always looking to connect with more faculty and students who have innovative ideas that can benefit society, so we can help them determine whether there’s a commercial opportunity for their innovation and, if so, a path to market.”




Filters close

Showing results

110 of 4146
Newswise: Long-Term Impacts of COVID-19: Your Mental Health
Released: 25-Nov-2020 2:15 PM EST
Long-Term Impacts of COVID-19: Your Mental Health
Cedars-Sinai

The COVID-19 pandemic has shaped more than half a year of our lives, canceling plans, upending livelihoods and causing feelings of grief, stress and anxiety. And Cedars-Sinai mental health experts say the pandemic could be shaping our mental health well into the future.

Released: 25-Nov-2020 12:45 PM EST
SARS-CoV-2 mutations do not appear to increase transmissibility
University College London

None of the mutations currently documented in the SARS-CoV-2 virus appear to increase its transmissibility in humans, according to a study led by UCL researchers.

Newswise: COVID-19 vaccine candidate tested preclinically at UAB nears first clinical test in people
Released: 25-Nov-2020 11:05 AM EST
COVID-19 vaccine candidate tested preclinically at UAB nears first clinical test in people
University of Alabama at Birmingham

Maryland-based Altimmune Inc., a clinical stage biopharmaceutical company, has submitted an Investigational New Drug, or IND, application to the United States Food and Drug Administration to commence a Phase 1 clinical study of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.

Released: 25-Nov-2020 11:05 AM EST
BIDMC researchers reveal how genetic variations are linked to COVID-19 disease severity
Beth Israel Lahey Health

New research BIDMC-led sheds light on the genetic risk factors that make individuals more or less susceptible to severe COVID-19.

Newswise: blog-pandemic-scenario-planning-lg-feature2.jpg
Released: 25-Nov-2020 11:05 AM EST
Pandemic Ups Game on Scenario Planning in The Arts
Wallace Foundation

Researcher/Author of new toolkit and report seeks to help arts and culture organizations add scenario planning to their strategic toolbox

Released: 25-Nov-2020 10:30 AM EST
Young people's anxiety levels doubled during first COVID-19 lockdown, says study
University of Bristol

The number of young people with anxiety doubled from 13 per cent to 24 per cent, during the early stages of the COVID-19 pandemic and lockdown 1, according to new research from the University of Bristol.

Newswise: 249837_web.jpg
Released: 25-Nov-2020 10:20 AM EST
Tracking COVID-19 trends in hard-hit states
Louisiana State University

Currently, there are over 10 million confirmed cases and more than 240,000 casualties attributed to COVID-19 in the U.S.

Released: 25-Nov-2020 9:55 AM EST
More Health Systems Join National #MaskUp Campaign
Cleveland Clinic

Many more health systems are joining the national #MaskUp campaign encouraging Americans to stop the spread of COVID-19 by following safety guidelines. Over just a few days, another 19 health systems with hundreds of hospitals united with 100 health systems nationwide with hospitals numbering in the thousands. The public service campaign is critical to the health and well-being of all Americans. It is a plea from healthcare professionals everywhere: wear a mask and follow other precautions to save lives and help get our country back on its feet.

Newswise: delaterre_jpeg.jpg
Released: 25-Nov-2020 7:35 AM EST
Warwick scientists design model to predict cellular drug targets against Covid-19
University of Warwick

The covid-19 virus, like all viruses relies on their host for reproduction

access_time Embargo lifts in 2 days
Embargo will expire: 30-Nov-2020 10:00 AM EST Released to reporters: 24-Nov-2020 5:35 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 30-Nov-2020 10:00 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.


Showing results

110 of 4146

close
2.13921